Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2026)

Century Therapeutics (IPSC) has 3 years of Total Non-Current Liabilities data on file, last reported at $59.9 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $59.9 million, down 10.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.9 million (down 10.2% YoY), and the FY2025 annual result was $61.0 million, down 66.68% from the prior year.
• Total Non-Current Liabilities slipped to $59.9 million in Q1 2026 per IPSC's latest filing, from $61.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $185.0 million in Q2 2024 and troughed at $59.9 million in Q1 2026.
• A 3-year average of $116.0 million and a median of $67.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities tumbled 66.68% in 2025, then slipped 10.2% in 2026.
• A 3-year view of Total Non-Current Liabilities shows it stood at $183.1 million in 2024, then plunged by 66.68% to $61.0 million in 2025, then slipped by 1.87% to $59.9 million in 2026.
• Business Quant data shows IPSC's Total Non-Current Liabilities at $59.9 million in Q1 2026, $61.0 million in Q4 2025, and $67.6 million in Q3 2025.